Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Urigen raises $257,000 in financing
The proceeds from the financing will be used to provide the financial flexibility to advance partnering and M&A discussions for Urigen’s URG101 program for painful bladder syndrome and
The proceeds from the financing will be used to provide the financial flexibility to advance partnering and M&A discussions for Urigen’s URG101 program for painful bladder syndrome and
Under the terms of the agreement, AuricX gained rights from SRI to oral formulations of the antibiotic vancomycin. SRI received upfront payments and will be eligible for success-based
Based on positive initial treatments in a rat model of Parkinson’s disease, conducted by David Yurek at University of Kentucky, a second Phase of studies will now work
In addition, the company announced that the FDA has granted expedited review status to the Alair system. Bronchial thermoplasty with the Alair system is an investigational procedure that
Under the terms of the agreement, Forma will leverage its transformative biology and chemistry platform to develop inhibitors for an undisclosed protein-protein interaction target in the field of
The two companies have formed a global platform for the introduction of the Sohm brand of generic medicines into the African, Latin American, and Southeast Asian markets. Generic
The clinical trial is an international, multi-center, placebo-controlled study that will examine the effectiveness of SLC022 in controlling pain associated with post-herpetic neuralgia (PHN). Solace anticipates having results
Under the terms of the agreement Abbott receives a non-exclusive license to MethylPlex for in vitro molecular diagnostics to detect the presence or risk of prostate, bladder and
In his new role, Mr Ros will lead the US sales and marketing strategy of Boehringer Ingelheim’s core brands. Mr Ros has been with Boehringer Ingelheim for 14
Prior to joining Stem Cell Therapeutics (SCT), Mr Herring was the president, CFO and director of Atlas Minerals. Prior thereto Mr Herring was the CFO of Velo Energy,